Loading stock data…
RLYB
$14.00-0.38 (-2.64%)
After Hours$13.86-0.14 (-1.00%)· Last close May 11
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Rallybio Corporation in the Healthcare sector is trading at $14.00. The stock is currently near its 52-week high of $15.31, remaining 127.6% above its 200-day moving average. Technical signals show overbought RSI of 90 and bullish MACD crossover, explaining why RLYB maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 90) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$14.00
Potential Upside
5%
Whystock Fair Value$14.70
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibito...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$45.23M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-15.49%
Volume
Today's trading volume
176,413
Recent News
Rallybio to acquire Candid Therapeutics
The combined cash balance at closing is projected to fund operations through 2030.
Candid, in a reverse merger with RallyBio, to go public
Candid, which is making bispecifics for immune diseases, has also raised $505 million in a private financing for the newly formed company.
Stock Splits Matter: What’s Coming Up This Month?
Here is a look at why companies split their stocks and why it matters. Upcoming splits worth keeping an eye on include one by Southern Copper.
Does Short Squeeze Attention and AI Advances Alter the Bull Case for Recursion Pharmaceuticals (RXRX)?
In recent days, Recursion Pharmaceuticals attracted heightened attention as traders responded to the stock’s very large short interest, alongside the announcement of a $12.5 million milestone payment from Rallybio related to the advancement of REV102 for hypophosphatasia. An intriguing detail is that Recursion’s AI capabilities have expanded through the co-development of Boltz-2 with MIT, highlighting the company’s ongoing investment in cutting-edge drug discovery technology. We’ll explore...
Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances
In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Recursion Pharmaceuticals, Inc. is one of them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a clinical-stage biotech, is pioneering the use of artificial intelligence and machine learning to accelerate drug discovery, with a focus on rare diseases and oncology. […]